trending Market Intelligence /marketintelligence/en/news-insights/trending/jkqtZOe4usD_Do_vpT66lQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Foamix wins US FDA approval for acne drug Amzeeq

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Foamix wins US FDA approval for acne drug Amzeeq

Foamix Pharmaceuticals Ltd. said the U.S. Food and Drug Administration approved Amzeeq to treat moderate to severe acne in patients aged nine years and older.

The U.S. regulator authorized the use of Amzeeq, or minocycline, to treat inflammatory lesions due to acne. Minocycline is an antibiotic used for treating acne but had limited oral use due to side effects in certain patients.

Amzeeq, formerly known as FMX101, uses Foamix's proprietary technology to deliver the drug in a topical foam. This is the first topical minocycline to be approved by the FDA for any condition, according to an Oct. 18 news release.

The approval is based on results from three late-stage clinical trials of Amzeeq in acne patients aged nine years and older which showed that the drug significantly improved symptoms of the disease. The drug also showed significant improvement in clearing the skin of the patients.

The Israel-based company, which develops and commercializes treatments for skin conditions in the U.S. and Germany, expects to make the drug available in January 2020.